Cataplexy Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast
Cataplexy is sudden and uncontrollable muscle weakness or paralysis that comes on during the day and is often triggered by strong emotions, such as excitement or laughter. The vast majority of people who experience cataplexy do so as a result of having type 1 narcolepsy, a chronic sleep and neurological disorder in which the brain has trouble properly controlling wake and sleep cycles. In very rare cases, cataplexy has been reported in individuals without narcolepsy. The cause of this circumstance remains unknown.
Both cataplexy and narcolepsy with cataplexy can be treated with medication and lifestyle changes. Medications cannot cure cataplexy, but they can help manage the symptoms. Furthermore, Sodium oxybate has been approved by the US FDA for the treatment of cataplexy.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/cataplexy-market
The Cataplexy market report also covers emerging drugs, current treatment practices, Cataplexy market share of the individual therapies, current and forecasted Cataplexy Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Cataplexy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Cataplexy Market Key Facts
-
In the study titled “Clinical features and diagnosis of narcolepsy in adults”, Scammell (2020) stated that NT1 (narcolepsy with cataplexy) was estimated to have a prevalence of 25 to 50 per 100,000 people. It was found to be equally common in men and women. The study also suggests that narcolepsy typically begins in the teens and early twenties, but occasionally occurs as early as five years of age or after 40 years of age.
-
A study by Egel et al., (2012) titled “Isolated Cataplexy in the Differential Diagnosis of Drop Attacks: A Case of Successful Clinical Diagnosis and Treatment” suggested that the prevalence of cataplexy has been reported in up to 29% of young adults with associated excessive daytime sleepiness. However, the prevalence of isolated cataplexy is unknown.
-
Mirabile and Sharma (2020) in the study titled “Cataplexy”, stated that in the US, narcolepsy affects 1 in 2000 individuals with an equal distribution amongst the sexes. As per the study, symptom onset most frequently occurs during adolescence; however, diagnosis often gets delayed on average by 15 years. The study also highlights that there are two forms of narcolepsy, namely, type 1 which is associated with cataplexy while this feature is absent in type 2. In the US, type 1 narcolepsy affects 1 to 2 in 4000 individuals.
Key Benefits of Cataplexy Market Report
-
Cataplexy market report provides an in-depth analysis of Cataplexy Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Cataplexy market report will help in developing business strategies by understanding the Cataplexy Market trends & developments, key players, and future market competition that will shape and drive the Cataplexy market in the upcoming years.
-
The Cataplexy market report covers Cataplexy’s current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Cataplexy market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Cataplexy market size is expected to increase during the forecast period owing to the rise in the number of prevalent cases in the 7MM.
The Cataplexy market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Cataplexy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Cataplexy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Cataplexy Epidemiology
The Cataplexy epidemiology section covers insights about the historical and current Cataplexy patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Cataplexy Epidemiology Segmentation –
-
Prevalent Population of Cataplexy
-
Diagnosed Prevalent Population of Cataplexy
-
Treatable Cases of Cataplexy
Cataplexy Drugs Uptake and Key Market Players
The Cataplexy Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cataplexy market or expected to get launched in the market during the study period. The analysis covers Cataplexy market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamic of the Cataplexy market is anticipated to change in the coming years owing to the improvement in the research and development activities. The pipeline of Cataplexy possesses few potential key players and the launch of emerging therapies is expected during the forecast period.
Cataplexy Companies:
Avadel
Takeda
Axsome Therapeutics
Suven Life Sciences
And many others
Cataplexy Therapies covered in the report include:
AXS-12
SUVN-G3031
Tak-944
TAK-925
FT218
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Cataplexy Competitive Intelligence Analysis
4. Cataplexy Market Overview at a Glance
5. Cataplexy Disease Background and Overview
6. Cataplexy Patient Journey
7. Cataplexy Epidemiology and Patient Population
8. Cataplexy Treatment Algorithm, Current Treatment, and Medical Practices
9. Cataplexy Unmet Needs
10. Key Endpoints of Cataplexy Treatment
11. Cataplexy Marketed Products
12. Cataplexy Emerging Therapies
13. Cataplexy Seven Major Market Analysis
14. Attribute Analysis
15. Cataplexy Market Outlook (7 major markets)
16. Cataplexy Access and Reimbursement Overview
17. KOL Views on the Cataplexy Market.
18. Cataplexy Market Drivers
19. Cataplexy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/cataplexy-market
Latest Reports By DelveInsight –
Cataplexy Pipeline Insights
Cataplexy Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cataplexy market.
H3N2 Infection Market
DelveInsight’ s “H3N2 Infection Market Insights, Epidemiology, and Market Forecast 2030” report provide a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the H3N2 Infection market size, share, trends, and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
